Gilead Sciences’ (GILD) Sector Perform Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada restated their sector perform rating on shares of Gilead Sciences (NASDAQ:GILD) in a research report sent to investors on Monday morning, Benzinga reports. They currently have a $74.00 price objective on the biopharmaceutical company’s stock.

Several other research analysts have also recently weighed in on the stock. StockNews.com raised shares of Gilead Sciences from a buy rating to a strong-buy rating in a report on Saturday, April 27th. Wells Fargo & Company decreased their price objective on shares of Gilead Sciences from $84.00 to $77.00 and set an equal weight rating for the company in a report on Monday, March 4th. TD Cowen decreased their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a buy rating for the company in a report on Friday, April 26th. Oppenheimer reissued an outperform rating and set a $105.00 price objective on shares of Gilead Sciences in a report on Friday, April 19th. Finally, Maxim Group decreased their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a buy rating for the company in a report on Wednesday, May 1st. Twelve research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of Hold and a consensus price target of $83.47.

Gilead Sciences Stock Up 0.0 %

Shares of Gilead Sciences stock opened at $68.64 on Monday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.94 and a current ratio of 1.08. The stock has a market capitalization of $85.52 billion, a PE ratio of 190.67, a price-to-earnings-growth ratio of 2.92 and a beta of 0.18. Gilead Sciences has a 52-week low of $62.07 and a 52-week high of $87.86. The company has a 50-day simple moving average of $65.98 and a two-hundred day simple moving average of $72.51.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.49) by $0.17. The business had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the previous year, the company earned $1.37 earnings per share. On average, analysts anticipate that Gilead Sciences will post 3.75 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 27th. Shareholders of record on Friday, June 14th were given a dividend of $0.77 per share. The ex-dividend date was Friday, June 14th. This represents a $3.08 annualized dividend and a yield of 4.49%. Gilead Sciences’s dividend payout ratio (DPR) is currently 855.56%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Monday, July 1st. The shares were sold at an average price of $68.63, for a total transaction of $137,260.00. Following the completion of the transaction, the insider now owns 96,380 shares in the company, valued at $6,614,559.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.29% of the stock is owned by company insiders.

Institutional Investors Weigh In On Gilead Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Tompkins Financial Corp raised its holdings in shares of Gilead Sciences by 223.1% in the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 241 shares during the period. Fortitude Family Office LLC bought a new stake in shares of Gilead Sciences during the fourth quarter worth $29,000. Private Wealth Management Group LLC bought a new stake in shares of Gilead Sciences during the fourth quarter worth $29,000. Palisade Asset Management LLC bought a new stake in shares of Gilead Sciences during the first quarter worth $29,000. Finally, Sachetta LLC bought a new stake in shares of Gilead Sciences during the fourth quarter worth $30,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.